Your session is about to expire
← Back to Search
adalimumab for Focal Segmental Glomerulosclerosis
Study Summary
This trial is testing a new treatment to see if it changes urine biomarker levels. The outcomes may help develop individualized treatment options for future patients with a certain kidney disease.
- Focal Segmental Glomerulosclerosis
- Microcephaly-Capillary Malformation Syndrome
- Nephrotic Syndrome
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 4372 Patients • NCT02092467Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- is a critical part of reducing unintended pregnanciesis not a contraindication to treatment with rituximab
Patients with Minimal Change Disease who have a history of resistance to corticosteroid therapy do not need to avoid treatment with rituximab.The weight of an object is greater than 15 kg.
- Group 1: adalimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are currently enrolled in this research endeavor?
"Affirmative. According to the data hosted on clinicaltrials.gov, this medical study is presently recruiting participants in 4 different locations with a goal of 8 enrollees. The trial was first published October 2nd 2019 and last edited July 22nd 2022."
Do I meet the qualifications to register for this medical trial?
"Patients with nephrotic syndrome between 6 and 70 years of age may be eligible to join this clinical trial. It is currently looking for 8 participants in total."
Is eligibility for this trial restricted to those over 18 years of age?
"This trial has a narrow age range of between 6 to 70. However, there are numerous other studies tailored for children and the elderly; 46 for those below 18 and 127 specifically designed with seniors in mind."
To what extent is adalimumab a risk to human health?
"There is evidence that adalimumab presents some degree of safety, thus our team appraised its risk level at a 2. This evaluation was based on the fact that this drug has only been evaluated in Phase 2 trials and no efficacy data exists yet."
What other trials have yielded information about the effects of adalimumab?
"Currently, 50 separate clinical trials involving adalimumab are active with 14 of them in the third phase. Most of these studies originate from London but there are 2044 sites worldwide researching this medication."
What are the fundamental aims of this investigation?
"The primary evaluation criteria of this clinical trial, assessed between the initial study date and Week 10, is to measure alterations in urine TIMP1/Cr concentrations. Secondary objectives involve recording any adverse events (AEs) that occur during the course of treatment; assessing patients' nadir Urine Protein Creatinine Ratio (UPC); and calculating participants' estimated glomerular filtration rate (eGFR). Descriptively summarizing these results will include baseline data as well as follow-up information detailing changes from first measurements."
Is this clinical trial still accepting participants?
"Affirmative. The clinicaltrials.gov registry reveals that this research is currently recruiting participants, with the original listing posted on October 2nd 2019 and updated as recently as July 22nd 2022. Altogether, 8 individuals will be admitted across 4 sites for participation in this trial."
How is adalimumab commonly employed to address various illnesses?
"Adalimumab is regularly employed to address ankylosing spondylitis, as well as various other ailments such as rheumatoid arthritis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis."
Share this study with friends
Copy Link
Messenger